Lifecore Biomedical, Inc. (LFCR) stock
LFCRNasdaqPharmaceutical PreparationsFiscal year ends May 25
$6.40+0.00 (0.00%)
Close on Nov 12, 2026Market cap $242.26MP/E –Yield –
Lifecore Biomedical EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Lifecore Biomedical's EPS for the twelve months ending May 25, 2025 was -$1.27, down 484.8% year over year. For fiscal 2025 it was -$1.27, down 484.8% from the year before. The highest annual figure on record is $0.89 in fiscal 2018.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | May 25, 2025 | -$1.27 | -484.8% |
| FY2024 | May 26, 2024 | $0.33 | – |
| FY2023 | May 28, 2023 | -$3.32 | – |
| FY2022 | May 29, 2022 | -$3.97 | – |
| FY2021 | May 30, 2021 | -$1.10 | – |
| FY2020 | May 31, 2020 | -$1.31 | -13200.0% |
| FY2019 | May 26, 2019 | $0.01 | -98.9% |
| FY2018 | May 27, 2018 | $0.89 | +134.2% |
| FY2017 | May 28, 2017 | $0.38 | – |
| FY2016 | May 29, 2016 | -$0.43 | -186.0% |
| FY2015 | May 31, 2015 | $0.50 | -29.6% |
| FY2014 | May 25, 2014 | $0.71 | -16.5% |
| FY2013 | May 26, 2013 | $0.85 | +73.5% |
| FY2012 | May 27, 2012 | $0.49 | +226.7% |
| FY2011 | May 29, 2011 | $0.15 | 0.0% |
| FY2010 | May 30, 2010 | $0.15 | – |
Quarterly eps
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2027CQ1 2026 | Sep 30, 2026 | -$1.08 | – |
| Q4 FY2025CQ2 2025 | May 25, 2025 | -$0.06 | – |
| Q3 FY2025CQ1 2025 | Feb 23, 2025 | -$0.42 | -200.0% |
| Q2 FY2025CQ4 2024 | Nov 24, 2024 | -$0.25 | -164.1% |
| Q1 FY2025CQ3 2024 | Aug 25, 2024 | -$0.53 | – |
| Q4 FY2024CQ2 2024 | May 26, 2024 | -$0.19 | – |
| Q3 FY2024CQ1 2024 | Feb 25, 2024 | $0.42 | – |
| Q2 FY2024CQ4 2023 | Nov 26, 2023 | $0.39 | – |
| Q1 FY2024CQ3 2023 | Aug 27, 2023 | -$0.35 | – |
| Q4 FY2023CQ2 2023 | May 28, 2023 | -$1.32 | – |
| Q3 FY2023CQ1 2023 | Feb 26, 2023 | -$1.20 | – |
| Q2 FY2023CQ4 2022 | Nov 27, 2022 | -$0.43 | – |
| Q1 FY2023CQ3 2022 | Aug 28, 2022 | -$0.37 | – |
| Q4 FY2022CQ2 2022 | May 29, 2022 | -$1.88 | – |
| Q3 FY2022CQ1 2022 | Feb 27, 2022 | -$0.46 | – |
| Q2 FY2022CQ4 2021 | Nov 28, 2021 | -$1.31 | – |
| Q1 FY2022CQ3 2021 | Aug 29, 2021 | -$0.32 | – |
| Q4 FY2021CQ2 2021 | May 30, 2021 | -$0.04 | – |
| Q3 FY2021CQ1 2021 | Feb 28, 2021 | -$0.24 | – |
| Q2 FY2021CQ4 2020 | Nov 29, 2020 | -$0.40 | – |
| Q1 FY2021CQ3 2020 | Aug 30, 2020 | -$0.42 | – |
| Q4 FY2020CQ2 2020 | May 31, 2020 | -$0.52 | – |
| Q3 FY2020CQ1 2020 | Feb 23, 2020 | -$0.39 | -1075.0% |
| Q2 FY2020CQ4 2019 | Nov 24, 2019 | -$0.23 | – |
| Q1 FY2020CQ3 2019 | Aug 25, 2019 | -$0.16 | -1700.0% |
| Q4 FY2019CQ2 2019 | May 26, 2019 | -$0.01 | -104.5% |
| Q3 FY2019CQ1 2019 | Feb 24, 2019 | $0.04 | -93.0% |
| Q2 FY2019CQ4 2018 | Nov 25, 2018 | -$0.02 | -200.0% |
| Q1 FY2019CQ3 2018 | Aug 26, 2018 | $0.01 | -87.5% |
| Q4 FY2018CQ2 2018 | May 27, 2018 | $0.22 | +144.4% |
| Q3 FY2018CQ1 2018 | Feb 25, 2018 | $0.57 | +338.5% |
| Q2 FY2018CQ4 2017 | Nov 26, 2017 | $0.02 | -60.0% |
| Q1 FY2018CQ3 2017 | Aug 27, 2017 | $0.08 | -33.3% |
| Q4 FY2017CQ2 2017 | May 28, 2017 | $0.09 | -47.1% |
| Q3 FY2017CQ1 2017 | Feb 26, 2017 | $0.13 | – |
| Q2 FY2017CQ4 2016 | Nov 27, 2016 | $0.05 | – |
| Q1 FY2017CQ3 2016 | Aug 28, 2016 | $0.12 | – |
| Q4 FY2016CQ2 2016 | May 29, 2016 | $0.17 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?